Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study

Table 2 Associations between specific progesterone therapy^a and recurrent preterm delivery of index pregnancy at each of two timepoints

Treatment	< 34 weeks gestation		< 37 weeks gestation
Treatment	^bcOR (95%CI)	^caOR (95%CI)	cOR (95%CI)	aOR (95%CI)
Among all participants
IM 17-OHPC	1.89 (1.07, 3.45)	1.79 (0.89, 3.75)	1.43 (0.98, 2.08	1.47 (0.94, 2.31)
Vaginal Progesterone	0.41 (0.25, 3.37)	1.06 (0.23, 3.62)	0.58 (0.21, 1.35)	0.59 (0.21, 1.46)
Among those without short cervix
IM 17-OHPC	1.51 (0.79, 2.98)	1.71 (0.80, 3.84)	1.22 (0.80, 1.87)	1.36 (0.84, 2.20)
Vaginal Progesterone	0.94 (0.14, 3.53)	1.24 (0.18, 4.98)	0.54 (0.15, 1.44)	0.64 (0.18, 1.78)
Among those with short cervix
IM 17-OHPC	1.86 (0.42, 13.1)	2.24 (0.31, 45.50)	2.88 (0.84, 11.6)	5.61 (1.16, 42.9)
Vaginal Progesterone	0.72 (0.03, 8.70)	1.22 (0.04, 36.73)	0.69 (0.08, 4.49)	1.45 (0.13, 16.3)

CI confidence interval
^aCompared to reference group who received no treatment
^bcOR, crude odds ratio
^caOR, odds ratio adjusted for gestational age at earliest prior preterm delivery, short cervix, race, limited prenatal care

ISSN: 1471-2393